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Abstract
Background: For the nearly 75% of patients living with type 2 diabetes (T2DM) that do not use insulin, decisions
regarding self-monitoring of blood glucose (SMBG) can be especially problematic. While in theory SMBG holds
great promise for sparking favorable behavior change, it is a resource intensive activity without firmly established
patient benefits. This study describes our study protocol to assess the impact of three different SMBG testing
approaches on patient-centered outcomes in patients with non-insulin treated T2DM within a community-based,
clinic setting.
Methods/Design: Using stakeholder engagement approach, we developed and implemented a pragmatic trial of
patient with non-insulin treated T2DM patients from five primary care practices randomized to one of three SMBG
regimens: 1) no testing; 2) once daily testing with standard feedback consisting of glucose values being
immediately reported to the patient through the glucose meter; and 3) once daily testing with enhanced patient
feedback consisting of glucose values being immediately reported to the patient PLUS automated, tailored
feedback messaging delivered to the patient through the glucose meter following each testing. Main outcomes
assessed at 52 weeks include quality of life and glycemic control.
Discussion: This pragmatic trial seeks to better understand the value of SMBG in non-insulin treated patients with
T2DM. This paper outlines the protocol used to implement this study in fifteen community-based primary care
practices and highlights the impact of stakeholder involvement from the earliest stages of project conception and
implementation. Plans for stakeholder involvement for result dissemination are also discussed.
Trial registration: ClinicalTrials.gov NCT02033499, January 9, 2014.
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Background
Over the past decade the value of routine daily self-
monitoring of blood glucose (SMBG) in patients with type
2 diabetes (T2DM) not treated with insulin has been con-
tentiously debated [1–8]. Proponents postulate that testing
promotes better awareness of glucose levels, leading to
improvements in diet and lifestyle. When test results are
shared with health care providers, it is argued, there is also
the potential for more timely treatment modification.
Competing arguments point to the costs of SMBG, both
in terms of supplies (test strips and meters) and time, as
well as discomfort and potentially quality of life. As a
result no clear consensus exists regarding SMBG monitor-
ing in non-insulin treated patients with T2DM.
In an attempt to make SMBG more convenient and
patient-centric, much effort has been placed in improving
SMBG technology [9]. Early studies that marry technology
and SMBG been mixed, with some showing a benefit on
glycemic control and others showing no benefit [1, 10].
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Few trials have pragmatically assessed the utility of SMBG
monitoring in real-life settings, like the busy primary care
practice where the majority of non-insulin treated patients
with T2DM are managed. With patients taking a more
directive role in their health care, a large focus is being
placed on how usable these glucose-monitoring tools are
in the real world. Few studies have focused on the health
care provider side of this issue. In fact, studies of
‘enhanced’ SMBG, where both the patient and the pro-
vider were engaged in SMBG interpretation, found A1c
reductions along the magnitude of 0.5% [4, 11–13]. As
additional ‘enhanced’ intervention SMBG studies have
been added to the literature [13, 14], more recent reviews
and meta-analyses have drawn conclusions more in favor
or testing [4, 15]. This pattern suggests that, for SMBG to
be an effective self-management tool in non-insulin
treated T2DM, the patient and the health care provider
must both actively engage in performing, interpreting, and
acting upon the SMBG values.
Given these unanswered questions regarding the im-
pact of SMBG on patient quality of life and other patient
reported outcomes, there is a growing interest by
patients and other stakeholders who are looking for data
that will help them make better, informed decisions
about their self-care when no standard of care exists and
providers make recommendations based upon their ex-
perience and preferences, like SMBG monitoring in
T2DM. Our overarching goal is to answer the following
questions: Is SMBG testing effective for people with
non-insulin treated T2DM in terms of either A1c or
quality of life (QOL)? We will also examine outcomes
from SMBG in patients with different baseline character-
istics. Our primary outcomes include change in glycemic
control over 52 weeks and change in QOL over 52
weeks. The purpose of this paper is to describe our study
methods and the unique aspects of stakeholder engage-
ment that have been employed during the design and
implementation of the study.
Methods/Design
Study overview
The overarching goal of this proposal is to assess the
impact of three different SMBG testing approaches on
patient-centered outcomes in patients with non-insulin
treated T2DM within the real-world, clinic setting. In this
pragmatic trial, 450 patients will be randomized to one of
the following three SMBG testing regimens: 1) no SMBG
testing, 2) once daily SMBG testing with standard patient
feedback consisting of glucose values being immediately
reported to the patient through the glucose meter, and 3)
once daily SMBG testing with enhanced patient feedback
consisting of glucose values being immediately reported to
the patient PLUS automated, tailored feedback messaging
following each SMBG testing event delivered to the
patient through the glucose meter.
Recruitment
We will recruit 450 patients from primary care practices
within the central North Carolina area. Patients will be
randomized to one of the three study arms: 1) no SMBG
testing; 2) once daily SMBG testing with standard patient
feedback which includes the current glucose value; and 3)
once daily SMBG testing with enhanced patient feedback
which includes the current glucose value and a personal-
ized message about the current glucose value. We have
elected to use an FDA approved, cellularly-enabled gluc-
ometer device given its capabilities to deliver messaging to
patients in real time. Participants in both the standard
feedback and enhanced feedback groups will all receive
the glucometer. Patients will be followed for 1 year. The
first two study groups represent SMBG testing approaches
commonly utilized in clinical practice, while the third
incorporates cutting edge glucose monitoring tools now
on the market. During routine clinic visits, health care
providers will be guided to modify therapies based upon
American Diabetes Association (ADA) guidelines, which
focus on A1c values and SMBG values if available.
Patients in groups 2 and 3 will also receive training in
obtaining and interpreting SMBG values. SMBG values
will be systematically evaluated at routine clinic visits.
Stakeholder Engagement
As part of this grant, stakeholders were encouraged to
play a role in providing perspective to the research ques-
tions and methodologies chosen, and patient related out-
comes. There were several stakeholders that provided a
critical role in providing care advocacy and education
for persons with diabetes in North Carolina, which
included patient groups community members at risk
individuals policy makers providers industry and profes-
sional organizations. Given all of these stakeholder
groups involved in the area of diabetes we chose a broad
yet appropriately sized swath of this community. This in-
cluded the North Carolina Diabetes Advisory Council, a
patient advisory board, a community advisory board,
health care providers, American diabetes Association
representative, National Diabetes Education Program
representation, as well as patients involved in the
Diabetes registry and Glucometer manufacturers. Two
primary methods were planned for continuing collabor-
ation with these stakeholder groups. This included
attending regularly scheduled meetings the larger orga-
nizations on a pre-stipulated basis and holding key
stakeholder teleconferences with a small group (~10) of
representative stakeholders.
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Patient identification and recruitment
A multi-pronged approach will be utilized to identify
study participants. First, patients who have non-insulin
treated T2DM will be identified using the Carolina Data
Warehouse (CDW) or by chart review in the participat-
ing practice. Patients will receive an invitation letter by
mail, signed by their health care provider describing the
study. Any patient not interested in participating will be
able to opt out of further contact by returning a post
card or calling a toll-free number. If no opt out call is
made within 1 week of sending the letter, telephone con-
tact will be attempted on up to three different occasions
at three different times of day. Second, we will place
recruitment flyers within the participating practices that
will be visible in waiting areas and exam rooms. Clinic
staff will be encouraged to discuss the study with poten-
tially eligible patients during routine clinic activities (i.e.
while collecting vital signs and during check-in or
check-out). The UNC field coordinators will communi-
cate regularly with practice staff regularly regarding
potentially eligible
All potentially eligible patients will be screened for eli-
gibility by phone call. Overall inclusion and exclusion
criteria are listed in Table 1. The call will take about 15
min, during which a member of the study team describes
the study, answer questions, and conducts a short set of
simple screening questions. Eligible interested patients
complete an assessment visit with a research coordin-
ator. To decrease patient burden and further engage
participating practices, assessment visits occur at the
patient’s primary care office. Assessments are separate
from their appointment with their primary care provider,
and may or may not occur on the same day as a regu-
larly scheduled clinic visit, though for patient conveni-
ence we make every effort to coordinate the assessments
with a regular clinic visits. During these assessments, the
research coordinator reviews the study details in greater
depth, verify all inclusion and exclusion criteria, and
obtain written informed consent.
Data collection
Baseline
Eligible patients interested in enrolling for the study are
subsequently scheduled for the initial visit with the study
Field Coordinator. During this initial visit, the Field
Coordinator reviews and obtains written informed con-
sent from the patient. A signed copy is provided to the
participant. After written informed consent has been
received, blood samples are obtained along with height
and weight. Standardized surveys are completed, and
patients have the option of completing them independ-
ently or with the assistance of the Field Coordinator.
Randomization
After providing informed consent, baseline A1c, and
completing the baseline study interview, participants will
be randomized to one of the three treatment arms using
sequentially numbered, opaque, sealed envelopes. The
allocation sequence is generated using computer-
generated randomly permuted blocks of random sizes.
The randomization is stratified by study practice. The
Field Coordinator reviews the treatment assignment
with the patient, using a standardized script, provide the
initial training and supplies necessary for participation in
the study and answer any remaining questions (Fig. 1).
52 week follow-up
Patient will have blood drawn for a A1c. Patient partici-
pants will complete a follow-up interview that includes
demographic, health history, and quality of life ques-
tions. Weight measurement will be collected.
Measures
The two primary outcomes of the study are change in
A1c and change in health related quality of life
(HRQOL). The A1c was chosen due to its use in prior
studies and its standing as a measure on which: 1) pro-
viders evaluate patients; 2) payers evaluate providers;
and 3) patients evaluate themselves and their providers
[2]. Though HRQOL is also critically important to
patients, few studies have rigorously examined the im-
pact of SMBG on HRQOL. Based on these facts and the
recommendations of our stakeholder groups, HRQOL is
a co-primary outcome for this pragmatic trial. We will
utilize the Short Form 36 (SF-36) to assess overall qual-
ity of life. We will use the physical component score
(PCS) and the mental component score (MCS), with
scores standardized to a normal distribution (mean = 50
and standard deviation[SD] = 10) [16]. It has been widely
used and validated in medical studies generally and
diabetes studies in particular [17–20]. All primary and
secondary outcomes are outlined in Table 2. Because the
52-week time point may not align with a scheduled
Table 1 Monitor trial inclusion and exclusion criteria
Inclusion Criteria Exclusion Criteria
T2DM diagnosis
Age ≥ 30
Sees an endocrinologist or
other diabetes specialist
An established patient at the
participating practice
Use of insulin.
≥ 6.5% but ≤ 9.5% Pregnancy
Willing to comply with random
assignment into a study group
Plans to relocate in the next 12
months.
No history of significant issues with
hypoglycemia
Has other conditions (e.g. renal or
cardiovascular disease), factors
(e.g. frailty) or comorbidities
(e.g. cancer) that might put the
patient at risk
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primary care visit, we have defined this time point as 52
± 6 weeks from the baseline visit.
The following secondary endpoints will be collected
from patient participants at baseline and 52-weeks. 1)
Problem Areas in Diabetes (PAID) to assess psycho-
logical and social stress associated with diabetes [21–23],
2) Diabetes Symptom Checklist (DSC) to measure of
diabetes-related symptom frequency and perceived
severity during the prior month covering six symptom
categories: hyperglycemic, hypoglycemic, cardiac, neuro-
pathic, psychological, and vision-related [24–26] 3)
Summary of Diabetes Self Care Activities (SDCA) survey
to measure self-management activities (diet, exercise,
blood glucose testing, foot-care, and smoking status and
a supplemental medication adherence question [27], 4)
the Diabetes Treatment Satisfaction Questionnaire
(DTSQs) standard version to assess this diabetes treat-
ment satisfaction [28], 5) Diabetes-Specific Self-Efficacy
using the Diabetes Empowerment Scale Short Form
[29], 6) Patient-Provider Communication using the
Communication Assessment Tool [30].
Hypoglycemia Frequency
At the 52-week follow-up visit, participants are asked to
report the number of hypoglycemic episodes that
required intervention by a caregiver or by medical or
paramedical personnel since enrolling in the study. For
each episode, the participant will be asked whether EMS
was called or led to an urgent care clinic or emergency
department visit, or hospitalization. Each report is
reviewed by the study principal investigators and co-
investigator to determine whether the event is study
related. A summary report is submitted to the UNC
Institutional Review Board.
Health Care Utilization
Utilization outcomes will include inpatient, outpatient
and emergency department utilization during the 52-
week study period. UNC visits will be collected through
the EHR while non UNC visits will be captured at the
52 week study visit via patient interview with the study
coordinator.
Fig. 1 Study Arms
Table 2 Primary and secondary patient-centered outcomes
Clinical Outcomes Time Patient Reported Outcomes Time
Primary Glycemic control (A1c) Baseline/52 weeks Quality of life (QOL) Baseline/52 weeks
Secondary Hypoglycemia frequency Baseline/52 weeks DM-related QOL Baseline/52 weeks
Health care utilization Baseline/52 weeks DM self-care Baseline/52 weeks
Treatment regimen modification Baseline/52 weeks DM treatment satisfaction Baseline/52 weeks
DM-related self-efficacy Baseline/52 weeks
Patient-provider communication Baseline/52 weeks
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Adverse Events
Any reported adverse events will be categorized as re-
lated or not related to the study intervention by the in-
vestigators. These events will be reported in real time to
the principal investigators for confirmation and review.
Regardless of causality, all unanticipated Serious Adverse
Events will be reported to the IRB for review.
Qualitative Assessment
To gain a deeper understanding of patients’ and health
care providers’ experiences with each of the SMBG test-
ing approaches, including facilitators and barriers to dis-
semination, we will conduct focus group discussions at
the UNCPN practices.
Qualitative Assessment of Patient Outcomes Individ-
ual phone interviews will be conducted by researchers
skilled in qualitative data collection. At each participat-
ing practice, we will interview approximately 6 patients
who have completed the study. Two patient partici-
pants from each arm will be recruited for each of the
13 practices (N = 78 patients). Every effort will be made
to recruit a range of high and low engagement for test-
ing arms. Interviews will last approximately 30–45 min
and will include these topics: impressions of and
experience with SMBG prior to and during the trial,
including using a wireless glucometer and messaging
system, and impressions of using the downloaded
SMBG reports at clinic visits, interactions with pro-
viders about diabetes care before and during the study,
and strategies for dissemination and communication.
All participants will review, sign, and be given a copy of
the IRB-approved informed consent document specific
to the focus groups.
Qualitative Assessment of Health Care Provider Out-
comes Focus groups (one per practice) with 5–10 physi-
cians and nursing staff will also be conducted. by
researchers skilled in qualitative data collection. Focus
groups will be conducted once at least 80% of that prac-
tice’s enrolled study participants will have completed
their 52-week follow-up visit. Key discussion topics will
include: impressions regarding the usefulness of SMBG
summary reports and accompanying treatment algo-
rithm; experience with recommending SMBG for
patients with NIT DM prior to and during the trial (and
for both enrolled and non-enrolled patients); and per-
ceived benefits/problems arising from being a practice
site for this study. All participants will review and sign
IRB-approved informed consent documents prior to
participation. We will also collect age, gender, race/eth-
nicity, full-time/part-time employment status, years in
practice, and area of practice.
Sample Size
We desire high power for our primary between-arm
comparison as well as reasonable power to detect an im-
portant effect modifier, should one exist. In a recent
Cochrane Review, the estimated mean 12-month differ-
ences between SMBG and control groups were−0.13 and
−0.52%, respectively, for patients diagnosed more than
and less than 1 year prior to the study [1]. Assuming ap-
proximately equal enrollment of newly diagnosed and
long term patients, this implies a mean difference of
−0.325%. Based on results from one of the larger and
better quality trials conducted to date, we assume the
standard deviation for ΔA1c would be 0.8% [4]. We as-
sume no more than 10% loss to follow-up. Given these
assumptions, randomizing 150 patients per group would
provide at least 90% power for the primary comparison
for A1c at the 0.05 significance level. This same sample
size would provide at least 80% power for the primary
comparison if the true standard deviation were as high
as 1.0%. For comparing mean change in HRQOL be-
tween groups, we will use the physical and mental com-
ponent scores of the SF-36, both of which range from 0
to 100. Because we are interested in two different as-
pects of QOL, we will apply a Bonferroni correction and
assess each comparison at the 0.025 level. Based on ob-
served results from the ZODIAC-17 SMBG study, we
conservatively assume that the standard deviation for
the change scores for either component will be 10 points
[2]. Under these assumptions, randomizing 150 patients
per group with no more than 10% loss will provide at
least 80% power to detect an overall difference between
groups if the mean difference between the highest and
lowest groups is at least 4 points.
Data Management and Statistical Analysis Plan
All data will be systematically coded and double-entered
into a data system stored on a secure server according
to institutional, state, and federal policies. Contact infor-
mation was obtained from electronic health records and
stored on a secure, password-protected server with ac-
cess limited to study staff and will be destroyed after 5
years as required.
A detailed statistical analysis plan, finalized prior to
enrolling the first patient, is available from the authors
upon request; here, we provide key elements of that plan
for analysing the co-primary outcomes. The biostatisti-
cian and principal investigators are blinded to treatment
assignments, but the study field staff are not blinded.
For primary analyses, all randomized patients will be
analysed according to their randomized group regardless
of the extent to which they performed SMBG (intention-
to-treat). Missing 52-week outcome data will be ignored
for the primary analyses. First, we will compare change
in A1c from baseline through 52 weeks across the three
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randomization groups using an analysis of covariance
(ANCOVA) conducted at the 0.05 significance level.
This ANCOVA model will control for baseline A1c,
prior use of SMBG, duration of T2DM, baseline anti-
hyperglycemic treatment, age, race/ethnicity, health liter-
acy, and number of baseline comorbidities. If the overall
null hypothesis of no difference between the three
groups is rejected, we will compare each SMBG group
to the no testing group separately using the Dunnett-
Tamhane Step-Up procedure for multiple comparisons
to control the family-wise error rate at 0.05 (69). We will
also conduct a contrast test comparing the average of
the two SMBG groups to the no testing group at the
0.05 level. Similar ANCOVA models will compare
change in SF-36 physical and mental component scores
between groups, controlling for the same baseline vari-
ables as for A1c. Because we are examining two aspects
of HRQOL, we will apply a Bonferroni correction and
assess each comparison at the 0.025 level. We will not
adjust for multiple comparisons due to the co-primary
endpoints of A1c and HRQOL. In addition, we will as-
sess for potential effect modification for each of the
baseline variables included in the models by adding ap-
propriate interaction terms to the ANCOVA model one
at a time. Each interaction term will be tested separately
at the 0.05 significance level. Only if the associated inter-
action term is significant, similar contrasts to those
described above will be assessed within the relevant sub-
groups. Similar ANCOVA methods will be used to com-
pare groups on each of the secondary outcomes. These
tests will each be conducted at the 0.05 significance level
with no adjustments for multiple comparisons.
Baseline Statistics
Table 3 highlights the baseline statistics of the 450 sub-
jects that have been recruited into the study.
Discussion
Engaging Stakeholders
We designed the Monitor Trial using a pragmatic design
that was informed by our stakeholders. Increasingly or-
ganizations like the Patient Centered Outcome Research
Institute (PCORI) are encouraging the involvement of
stakeholders in all aspects of research from study incep-
tion, design, implementation, analysis, and dissemination
of results. Although the benefits and/or pitfalls of in-
cluding stakeholders broadly has yet to be fully under-
stood, this approach when executed effectively holds
great promise for helping patients and providers make
better, more informed choices about their health and
healthcare. Below we describe how we have engaged our
stakeholders to date and our plans for continued
engagement.
The study team engaged a multitude of stakeholders
during the inception of the study to ensure that issues
and outcomes that mattered most to patients and heath
care providers were fully considered. We engaged
patients primarily via two avenues. First we attended
two Patient Advisory Board (PAB) meetings to interact
in real-time with patients, care givers and community
members affected by diabetes. We also electronically
surveyed patients from the UNC Diabetes Care Center
Patient Registry, which at the time of the survey include
over 2000 patients with diabetes across North Carolina.
From these interactions we learned that there is a per-
ceived direct link between SMBG and quality of life.
Additionally the feedback we received confirmed our
beliefs that quality of life is important to patients. Regis-
try respondents reported that they would use SMBG
more frequently if it held the potential to positively im-
pact quality of life. During discussions with the PABs the
topic of patient-provider communication arose. Insights
from patients and caregivers highlighted the fact that
patient-provider communication is an important issue
and that avenues to improve this should be developed. It
was viewed that consistently reviewing SMBG results to-
gether is an opportunity to build partnerships between
patients and their health care providers. Registry respon-
dents underlined current inconsistencies related to how
SMBG values are utilized during clinic visits. Most
(59%) reported that they believed it was important for
medical providers to review SMBG values, but only 38%
reported their health care providers always reviewed
SMBG logs and provided feedback. Based upon this
feedback we solidified the study team’s initial premise
that for SMBG to be effective, both the patient and pro-
vider must be engaged in the process and as a result de-
signed the study to include treatment recommendations
that would be generated for each health care provider at
the time of the clinic visit. These treatment recommen-
dations are intended to serve as a guide to inspire
discussion between patients and health care providers.
To objectively capture this, we included a measure of
patient-provider communication that is completed at
baseline and end of study. We will be collecting qualita-
tive data related to this topic at the conclusion of the
study as well to provide greater insight.
Input from health care providers was also utilized dur-
ing the design of this project. Early on the study team
engaged the UNCPN membership during a large
network-wide meeting. We discussed with the providers
the varied recommendations made to patients related to
SMBG monitoring in the real-world setting. Providers
reported that the believed the primary question of
SMBG monitoring effectiveness in T2DM to be an un-
settled, high priority topic in primary care. This message
was underscored by findings from the registry. Of the 62
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Table 3 Baseline interview
Mean (sd) Min Max N (%) # Missing
Demographics
Age (years) 60.5 (11.5) 30.8 91.8
Male 207 (46.0)
Race
American Indian or Alaskan Native 3 (0.7)
Asian 9 (2.0)
Black or African-American 148 (33.0)
Native Hawaiian/
Pacific Islander
1 (0.2)
White 279 (62.3)
Other (African, Filipino, Hispanic) 3 (0.7)
Multiracial (1 = white + other, Indian) 5 (1.1)
Refused (e.g., human race) 2
Ethnicity
Latino/Hispanic 8 (1.8) 1
Education
Less than high school graduate 25 (5.6)
High school graduate or GED 107 (23.8)
Some college or associate’s degree 164 (36.5)
4-year college degree 92 (20.5)
Graduate degree 61 (13.6)
Refused 1
Marital status
Married 292 (64.9)
Widowed 37 (8.2)
Living together 4 (0.9)
Single 64 (14.2)
Separated 7 (1.6)
Divorced 46 (10.2)
Comorbidities
# comorbidities 3.4 (1.8) 0 10
Heart disease 86 (19.2) 1
High blood pressure 340 (75.6)
Lung disease 30 (6.7)
Stroke 29 (6.4)
High Cholesterol 299 (67.0) 4
Kidney disease 32 (7.1)
Liver disease 18 (4.0)
Anemia or other blood disease 61 (13.6)
Cancer 76 (16.9)
Depression/anxiety 139 (30.9)
Arthritis 210 (46.8) 1
Chronic back pain 112 (24.9)
Autoimmune disease 14 (3.1)
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Table 3 Baseline interview (Continued)
Stomach or bowel disease 83 (18.4)
Healthcare utilization
Have you seen your primary care provider? 3.7 (2.4) 1 30
Have you gone to an urgent care clinic? 0.5 (1.1) 0 12
Have you been seen in the Emergency Room 0.4 (1.1) 0 12
Have you been hospitalized overnight? 0.2 (0.5) 0 6
Have you had someone call EMS for you? 0.1 (0.4) 0 5
DM-related
Nephropathy or other diabetes-related kidney disease 11 (2.4)
Diabetic retinopathy or other diabetes-related eye disease 20 (4.4)
Neuropathy or other diabetes-related nerve damage 65 (14.4)
Years with T2DM diagnosis 8.2 (7.6) 0.1 50.0
# Testing = Yes 338 (75.1)
If yes, how often: at least daily 129 (38.2)
If yes, how often: not daily, but > 1X/week 117 (34.6)
If yes, how often: a few times a month 50 (14.8)
If yes, how often: once a month 21 (6.2)
If yes, how often: less than once a month 21 (6.2)
If yes, how often told: at least daily 187 (55.5)
If yes, how often told: not daily, but > 1X/week 53 (15.7)
If yes, how often told: a few times a month 14 (4.2)
If yes, how often told: once a month 2 (0.6)
If yes, how often told: < once a month 1 (1.2)
If yes, how often didn’t know 77 (22.9)
If Testing = No, ever tested? 78 (69.6)
If yes, at least daily 55 (70.5)
If yes, not daily, but > 1X/week 10 (12.8)
If yes, a few times a month 3 (3.9)
If yes, once a month 1 (1.3)
If yes, less than once a month 9 (11.5)
If yes, how long did you test: <= 1 month 8 (10.3)
If yes, how long did you test: <1 year >1X/month 35 (44.9)
If yes, how long did you test: 1 year 12 (15.4)
If yes, how long did you test: > 1 year < 5 years 17 (21.8)
If yes, how long did you test: > = 5 years 6 (7.7)
# Testing = No, why not? 112 (24.9)
Not told to test 50 (44.6)
Costs 18 (16.1)
Pain 8 (7.1)
Disruptive 4 (3.6)
Does not understand why should test 7 (6.25)
Constant reminder of DM 10 (8.9)
Other reason 30 (26.8)
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registry respondents with T2DM not using insulin, 90%
reported that they included SMBG as part of their self-
care plan. Self-reported SMBG frequencies were: daily,
37.5%; several times per week, 37.5%; several times per
month, 20%, and less than once per month, 5%. The
other main take home point distilled from our conversa-
tions with providers related to the need for the proposed
study to be “efficient” and minimally disruptive to the
day-to-day clinic flow. This feedback guided the inter-
vention development. Additional feedback during the
planning phase of the MONITOR Trial was obtained by
several other organizations outlined in Table 4.
We continue to engage the stakeholders during the
grant process with periodic phone calls where they have
provided input on that best methods of patient recruit-
ment, dissemination opportunities, patient scripts used
during the baseline interview process. The overall goal
of involving various stakeholder groups is to have key
people with a variety of perspectives involved in plan-
ning, oversight, analysis, and dissemination. We consider
this collaboration essential for not only designing and
conducting research study that is responsive to the
needs and practical question non-insulin treated type 2
diabetes patient’s and caregivers daily but also to dissem-
inating our findings.
Clinical Implications
Self-monitoring of blood glucose in patients with dia-
betes has traditionally been considered to be a pillar of
diabetes self-care. Scientific examinations of SMBG in
T2DM have provided mixed results. An early epidemio-
logical evaluation of the issue using a retrospective,
longitudinal analysis showed that nonfatal micro- and
macrovascular event rates along with fatal event rates
were lower in individuals performing SMBG routinely as
compared to those who were not [3]. A multitude of
clinical trials followed. Several showed a significant
benefit from SMBG testing on improving glycemic con-
trol [4–7], while others found no evidence of benefit
[16]. In fact, some studies even suggested harm from
routine SMBG in patients with T2DM, specifically,
Table 3 Baseline interview (Continued)
Medications and BMI
# of prescription medications 6.2 (3.4) 0 17
# of DM medications 1.4 (0.9) 0 5
BMI (max weighs 523 lb) 34.3 (7.7) 20.8 75.0
Primary Endpoints
Hemoglobin A1c (%) 7.6 (1.1) 5.7 13.1
SF36—Physical Health 47.4 (8.9) 10.4 63.0
SF36—Mental Health 53.3 (9.2) 9.5 68.0
Secondary Endpointsa
Diabetes Empowerment Scale—Short Form 4.3 (0.5) 1.1 5 1
Diabetes Symptom Checklist—Revised 20.4 (21.4) 0 107.2
Diabetes Treatment Satisfaction—satisfaction 31.8 (5.1) 6 36 6
Diabetes Treatment Satisfaction—perceived control 2.7 (2.6) 6 12 23
Problem Areas in Diabetes 13.1 (16.2) 0 82.5
Summary of Diabetes Self-Care Activities (SDSCA) (# of days in last 7)
General Diet 4.3 (2.2) 0 7 1
Special Diet 4.1 (1.8) 0 7
Carb spacing 4.1 (2.4) 0 7
Exercise 2.9 (2.2) 0 7
Blood glucose testing (only # times tested) 2.6 (2.8) 0 7 1
Foot care 3.2 (2.5) 0 7
Communication Assessment Tool—MD items 4.5 (0.7) 1.5 5 1
Communication Assessment Tool—staff item 4.6 (0.7) 1 5
Health Literacy
Newest Vital Sign 3.8 (2.0) 0 6 2
Newest Vital Sign (% >4 = literate) (median = 4) 235 (61.8) 2
aMin/max may contain a decimal if missing data within the allowable limit were present
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higher rates of depression and increased cost without ac-
companying benefits [31].
Given these mixed results, a series of meta-analyses
and systematic reviews were conducted to investigate
the benefit or lack thereof of SMBG on glycemic lower-
ing in patients with T2DM [1, 9, 11–14]. While meta-a-
nalyses can be a useful way to assess the clinical
effectiveness of an intervention, they are limited by the
quality and comparability of the clinical trials included
in the analyses. Issues of sample size, duration/details of
the intervention, and patient characteristics (e.g., newly
diagnosed vs. longer duration of disease; baseline A1c
level), varied considerably across the available studies.
Given these critical differences, it is perhaps not surpris-
ing that the results of the meta-analyses have also shown
conflicting results. However, the overall conclusion has
been that SMBG is likely not cost effective for this popu-
lation of patients [1, 9, 12].
Perhaps most important to understanding these mixed
results is the fact that the question being addressed by
the studies is itself not consistent, falling generally into
two camps: ‘simple’ SMBG and ‘enhanced’ SMBG. In
studies testing simple SMBG, patients conducting SMBG
were compared to patients who were not. In evaluations
of ‘enhanced’ SMBG, intervention group patients and/or
providers were given education or feedback such that
they were better able to interpret SMBG results and use
them in a meaningful way with regard to lifestyle
changes and treatment modification. Among tests of
‘simple’ SMBG, A1c levels were reduced on average by
0.2%, an amount that was statistically significant in these
studies, but of doubtful clinical significance [12, 13].
Studies of ‘enhanced’ SMBG found A1c reductions
closer to 0.5% [7, 12, 15, 16]. As additional ‘enhanced’
intervention SMBG studies were added to the literature
[13, 14], more recent reviews and meta-analyses have
drawn conclusions more in favor or testing [4, 15]. This
pattern suggests that, for SMBG to be an effective self-
management tool in T2DM, the patient and the health
care provider must both actively engage in performing,
interpreting, and acting upon the SMBG values.
In an attempt to make SMBG more convenient and
patient-centric, much effort has been place in improving
the technology supporting SMBG. Like their non-
technological predecessors the results from these early
studies that marry technology and SMBG in an effort to
make the process more convenient have been mixed,
with some showing a benefit on glycemic control and
others showing no benefit. With patients’ taking a more
directive role in their health care, a large focus is being
place on how usable these glucose-monitoring tools are
in the real world. Generally speaking many of the appli-
cations need to focus on improved usability, perceived
usefulness, and sustained adoption of the technologies
[6]. Web-based applications, applications with easy-to-
use mechanisms, and applications without location
restrictions (can be used at home) have been most useful
[7]. Furthermore, few studies have focused on the health
care provider side of this issue. Allowing consistent, has-
sle free access to SMBG values for providers is an
equally important part of the equation. In fact, studies of
‘enhanced’ SMBG, where both the patient and the pro-
vider were engaged in SMBG interpretation, found A1c
reductions along the magnitude of 0.5% [7, 12, 15, 16].
As additional ‘enhanced’ intervention SMBG studies
have been added to the literature [13, 14], more recent
reviews and meta-analyses have drawn conclusions more
in favor or testing [4, 15]. This pattern suggests that, for
SMBG to be an effective self-management tool in non-
insulin treated T2DM, the patient and the health care
provider must both actively engage in performing, inter-
preting, and acting upon the SMBG values.
Table 4 Stakeholders and the input in the study design
Stakeholders Input provided How it shaped our design
Diabetes Advisory Council/
State Department of Health
(DAC)
Consider health literacy issues of patients
Policy subgroup would be useful to engage
for this work
- Engaged the Center for Diabetes Translation
and Research literacy core to join our team and
assist with message tailoring
- Tailoring algorithm that could be used in office
- Brought in Diabetes Advisory Council as a policy
subgroup
UNC Patient Advisory Board Emphasize quality of life questions (e.g, Can
I feel better or improve my ADLs?)
Added quality of life to outcomes
Greensboro Community
Advisory Board
Important outcomes: Quality of life, hypoglycemia,
health care service use, and patient empowerment.
CMEs for providers,
Query patient/provider community care
Hypoglycemia added as an outcome
CME added for providers
Added survey questions about patient-provider
communication
Diabetes Center Patient Database A1C is important in addition to Quality of life A1C designated as a primary outcome
UNCPN Medical Directors Testing is quite variable in real world clinical
settings
Designed three-armed plan to address this reality
and better respond to pragmatic patient issues.
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One issue often neglected in prior work is the fact that
SMBG could impact patient quality of life (QOL) both
positively and or negatively. Testing itself is a burden
and could act as a constant reminder of one’s less than
ideal health status [32]. On the other hand, testing may
provide a sense of agency, improving a patients self of
self-efficacy and hope for maximizing health and inde-
pendence into the future [32]. A recent Cochrane
Review identified only a handful of studies that had
examined health-related quality of life (HRQOL), well-
being, or patient satisfaction [1]. While these studies did
not find clinically relevant differences in HRQOL for
those who do or do not test, the review indicated future
research was needed [1]. In one study, HRQOL initially
decreased, but follow-up qualitative interviews showed
that patients in the testing groups experienced an in-
creased awareness of illness [4]. While both simple and
‘enhanced’ versions of SMBG were evaluated, the en-
hanced version included only training in the meaning of
the results and encouragement to explore how lifestyle
and dietary choices affect test values). Without more
hands-on use of results (e.g., reports provided to the
care provider), patients might have felt more ‘over-
whelmed’ than empowered by the experience of testing.
One of the key features of the MONITOR Trial is that
we are focusing on HRQOL and other patient-centered
aspects of SMBG and by the nature of the study design
we are examining the impact of this self-care activity
within the context of patient’s having actionable know-
ledge and improved opportunities for provider/patient
collaboration.
While researchers and medical organizations debate
the overall issue of the value of SMBG testing in NIT
DM, patients face this choice daily and without adequate
information as to its clinical or psychological outcomes.
For some patients, their decision on testing will mirror
that of their care provider. Yet more and more, patients
play an active role in managing their own health. To
some degree this is a necessary trend, because providers
simply do not have sufficient time to provide intensive
ongoing and comprehensive education and decision-
making around diabetes self-management. Then too,
even providers are looking for additional guidance on
this question, including how to present options to pa-
tients and incorporate test results into care [7]. The fact
that patients are taking a greater role in their health care
is generally positive, because those who do so also im-
prove their outcomes.
In order to make informed patient choices, patients and
their providers need accurate, generalizable and meaning-
ful information about the merits or demerits of SMBG
testing. Because the existing research, though relatively ex-
tensive, has not yet met this important need, more
research must be done on this issue. The Consensus
Report of the Diabetes Technology Society provides a list
of recommendations for future research relating to
SMBG. In regard to the intervention itself, they recom-
mend that it a) is linked to a structured program designed
to facilitate behavior change, b) has A1c as a primary end-
point but include patient-centered endpoints, c) include
encouragement and support, preferably in the form of per-
sonalized, automated feedback to patients in real time, d)
takes advantage of telemedicine opportunities, and d) in-
corporate best practices guidelines and standards for
physicians [4, 15]. Many of these recommendations over-
lap with others’ [32]. In addition to these critical features,
future research should be designed with a pragmatic eye,
adhering as closely as possible to the real world setting in
which SMBG would be carried out by patients and utilized
by patients and health care providers collaboratively. To
date, no large-scale, pragmatic RCT has evaluated the im-
pact of SMBG testing in patients with non-insulin treated
T2DM in which a multi-dimensional approach to SMBG
value management has occurred. This is the gap in know-
ledge that the MONITOR Trial will fill.
While SMBG may or not be worthwhile, effective
SMBG, if it exists for non-insulin treated T2DM, ap-
pears to require that it be embedded within the context
of patient education around the use and interpretation
of glucose readings, provider awareness of the results of
repeated testing, and collaborative use of this informa-
tion at medical visits [33]. We would also argue for pro-
viding treatment algorithms to providers that are based
on standard and accepted guidelines (such as the ADA
guidelines) linked to SMBG report results [34]. This step
facilitates the physician’s use of glucometer result reports
and can be used by health care providers during clinic
visits to better illustrate their concerns when talking to
patients. Finally, we feel it is important to evaluate
objectively and in a real world setting the possible add-
itional benefits of personalized feedback for patients in
the form of messages delivered via the glucometer based
on patients’ current and recent SMBG patterns. By
pointing out troubling patterns and rewarding results
that are at goal, this aspect of the approach we are call-
ing ‘enhanced feedback’ is akin to ‘mini consultations’
with a provider between routine clinic visits, which are
generally 3–6 months apart.
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